KR20240124391A - 상이한 약물 사용 패턴에 대한 표현형 측정값으로부터의 시간 데이터에 대한 공변량 보정 - Google Patents

상이한 약물 사용 패턴에 대한 표현형 측정값으로부터의 시간 데이터에 대한 공변량 보정 Download PDF

Info

Publication number
KR20240124391A
KR20240124391A KR1020247024939A KR20247024939A KR20240124391A KR 20240124391 A KR20240124391 A KR 20240124391A KR 1020247024939 A KR1020247024939 A KR 1020247024939A KR 20247024939 A KR20247024939 A KR 20247024939A KR 20240124391 A KR20240124391 A KR 20240124391A
Authority
KR
South Korea
Prior art keywords
drug
phenotypic
time point
computer
covariate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024939A
Other languages
English (en)
Korean (ko)
Inventor
페트코 플라메노프 피지에프
제레미 프란시스 맥레이
카이-하우 파
Original Assignee
일루미나, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일루미나, 인코포레이티드 filed Critical 일루미나, 인코포레이티드
Priority claimed from PCT/US2022/054196 external-priority patent/WO2023129622A1/en
Publication of KR20240124391A publication Critical patent/KR20240124391A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G16B30/10—Sequence alignment; Homology search
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
    • G16B5/10—Boolean models
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Chemical & Material Sciences (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Software Systems (AREA)
  • Artificial Intelligence (AREA)
  • Evolutionary Computation (AREA)
  • Pathology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
KR1020247024939A 2021-12-29 2022-12-28 상이한 약물 사용 패턴에 대한 표현형 측정값으로부터의 시간 데이터에 대한 공변량 보정 Pending KR20240124391A (ko)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US202163294816P 2021-12-29 2021-12-29
US202163294828P 2021-12-29 2021-12-29
US202163294827P 2021-12-29 2021-12-29
US202163294820P 2021-12-29 2021-12-29
US202163294813P 2021-12-29 2021-12-29
US202163294830P 2021-12-29 2021-12-29
US63/294,827 2021-12-29
US63/294,813 2021-12-29
US63/294,820 2021-12-29
US63/294,830 2021-12-29
US63/294,828 2021-12-29
US63/294,816 2021-12-29
US202263351317P 2022-06-10 2022-06-10
US202263351299P 2022-06-10 2022-06-10
US202263351283P 2022-06-10 2022-06-10
US63/351,299 2022-06-10
US63/351,283 2022-06-10
US63/351,317 2022-06-10
US17/968,766 US20230207132A1 (en) 2021-12-29 2022-10-18 Covariate correction including drug use from temporal data
US17/968,766 2022-10-18
PCT/US2022/054196 WO2023129622A1 (en) 2021-12-29 2022-12-28 Covariate correction for temporal data from phenotype measurements for different drug usage patterns

Publications (1)

Publication Number Publication Date
KR20240124391A true KR20240124391A (ko) 2024-08-16

Family

ID=86896998

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247024939A Pending KR20240124391A (ko) 2021-12-29 2022-12-28 상이한 약물 사용 패턴에 대한 표현형 측정값으로부터의 시간 데이터에 대한 공변량 보정
KR1020247024938A Pending KR20240124390A (ko) 2021-12-29 2022-12-28 희귀 변이체 다유전자 위험 점수
KR1020247025104A Pending KR20240131385A (ko) 2021-12-29 2022-12-28 보인자와 비보인자 사이의 분리를 최대화하는 네스팅된 t-검정에 기초한 최적화된 부담 검정

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247024938A Pending KR20240124390A (ko) 2021-12-29 2022-12-28 희귀 변이체 다유전자 위험 점수
KR1020247025104A Pending KR20240131385A (ko) 2021-12-29 2022-12-28 보인자와 비보인자 사이의 분리를 최대화하는 네스팅된 t-검정에 기초한 최적화된 부담 검정

Country Status (7)

Country Link
US (3) US20230207132A1 (cg-RX-API-DMAC7.html)
EP (5) EP4457829B1 (cg-RX-API-DMAC7.html)
JP (3) JP2025502816A (cg-RX-API-DMAC7.html)
KR (3) KR20240124391A (cg-RX-API-DMAC7.html)
CN (3) CN118451511A (cg-RX-API-DMAC7.html)
AU (3) AU2022426690A1 (cg-RX-API-DMAC7.html)
CA (2) CA3242597A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120977385B (zh) * 2025-10-20 2026-02-06 浙江博圣生物技术股份有限公司 一种单基因遗传病致病突变的打分排序方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1301633A1 (en) * 2000-07-21 2003-04-16 Althea Technologies, Inc. A systematic approach to mechanism-of-response analyses
WO2014110350A2 (en) * 2013-01-11 2014-07-17 Oslo Universitetssykehus Hf Systems and methods for identifying polymorphisms
CN111161799B (zh) * 2019-12-24 2023-12-15 大连海事大学 一种基于多组学数据获取多基因风险评分的方法及系统
WO2022020444A1 (en) * 2020-07-22 2022-01-27 Algen Biotechnologies, Inc. Methods and systems for determining drug effectiveness

Also Published As

Publication number Publication date
EP4457829C0 (en) 2026-02-04
CN118451511A (zh) 2024-08-06
EP4715828A2 (en) 2026-03-25
AU2022426690A1 (en) 2024-07-04
EP4457829B1 (en) 2026-02-04
US20230207052A1 (en) 2023-06-29
US20230207067A1 (en) 2023-06-29
KR20240131385A (ko) 2024-08-30
CN118451506A (zh) 2024-08-06
EP4457819A1 (en) 2024-11-06
CN118475982A (zh) 2024-08-09
EP4742250A2 (en) 2026-05-13
EP4457818B1 (en) 2025-12-24
EP4457818C0 (en) 2025-12-24
JP2025502818A (ja) 2025-01-28
CA3242597A1 (en) 2025-02-26
JP2025502816A (ja) 2025-01-28
US20230207132A1 (en) 2023-06-29
JP2025502817A (ja) 2025-01-28
AU2022429829A1 (en) 2024-07-04
EP4457818A1 (en) 2024-11-06
EP4457829A1 (en) 2024-11-06
EP4715828A3 (en) 2026-06-17
AU2022425376A1 (en) 2024-06-27
KR20240124390A (ko) 2024-08-16
CA3242710A1 (en) 2023-07-06
EP4742250A3 (en) 2026-07-22

Similar Documents

Publication Publication Date Title
US20230377691A1 (en) Estimating predisposition for disease based on classification of artifical image objects created from omics data
WO2023129621A1 (en) Rare variant polygenic risk scores
Xiong et al. scGHOST: identifying single-cell 3D genome subcompartments
US20230410941A1 (en) Identifying genome features in health and disease
US20250201348A1 (en) Artificial intelligence-based detection of gene conservation and expression preservation at base resolution
US20250218534A1 (en) Artificial intelligence-based epigenetics at base resolution
EP4457829B1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
Rahaie et al. DeepGenePrior: A deep learning model for prioritizing genes affected by copy number variants
US20240112751A1 (en) Copy number variation (cnv) breakpoint detection
Ye et al. Ge-SAND: an explainable deep learning-driven framework for disease risk prediction by uncovering complex genetic interactions in parallel
WO2023129622A1 (en) Covariate correction for temporal data from phenotype measurements for different drug usage patterns
WO2023129619A1 (en) Optimized burden test based on nested t-tests that maximize separation between carriers and non-carriers
Shafik et al. GENETIC BIOMARKERS DETECTION FOR ALZHEIMER’S DISEASE
CN119920308A (zh) 一种预测细胞系特异功能性非编码变异的方法
Nahlawi Increasing the Discovery Power and Confidence Levels of Disease Association Studies: A Survey
Kamboh et al. The application of network label propagation to rank biomarkers in genome-wide Alzheimer's data
Krol et al. Impact of missing genotype imputation on the power of Genome Wide Association Studies.

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000